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Abstract: Hypertensive disorders of pregnancy, including preeclampsia, are major 
contributors to maternal morbidity. The goal of this study was to evaluate the potential of 
metabolomics to predict preeclampsia and gestational hypertension from urine and serum 
samples in early pregnancy, and elucidate the metabolic changes related to the diseases. 
Metabolic profiles were obtained by nuclear magnetic resonance spectroscopy of serum 
and urine samples from 599 women at medium to high risk of preeclampsia (nulliparous or 
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previous preeclampsia/gestational hypertension). Preeclampsia developed in 26 (4.3%) and 
gestational hypertension in 21 (3.5%) women. Multivariate analyses of the metabolic 
profiles were performed to establish prediction models for the hypertensive disorders 
individually and combined. Urinary metabolomic profiles predicted preeclampsia and 
gestational hypertension at 51.3% and 40% sensitivity, respectively, at 10% false positive 
rate, with hippurate as the most important metabolite for the prediction. Serum metabolomic 
profiles predicted preeclampsia and gestational hypertension at 15% and 33% sensitivity, 
respectively, with increased lipid levels and an atherogenic lipid profile as most important 
for the prediction. Combining maternal characteristics with the urinary hippurate/creatinine 
level improved the prediction rates of preeclampsia in a logistic regression model. The 
study indicates a potential future role of clinical importance for metabolomic analysis of 
urine in prediction of preeclampsia. 
Keywords: NMR spectroscopy; preeclampsia; metabolomics; PLS-DA; gestational 
hypertension; prediction; first-trimester screening; biomarker 
 
1. Introduction 
Hypertensive disorders of pregnancy, including preeclampsia and gestational hypertension, are 
major causes of maternal morbidity and mortality, and affect up to 10% of pregnant women [1–3]. 
Early identification of women at high risk of preeclampsia might enable potential prophylactic 
treatment to reduce or avoid the onset of symptoms [4,5]. Late onset preeclampsia (occurring after  
34 weeks of pregnancy) is more common, and has lower detection rate [6]. Predictive models for late 
onset preeclampsia have employed a combination of maternal characteristics, biochemical and biophysical 
markers at 11+0–13+6 weeks of gestation, to predict the syndrome at 30%–60% sensitivity [5–8].  
Skråstad et al. [9] have previously found a combination of mean arterial pressure (MAP), maternal age 
and uterine artery pulsatility index (UtAPI) to be 38.5% predictive of preeclampsia in a cohort of 
women at gestational weeks 11+0–13+6. New and improved predictive biomarkers are warranted. 
Gestational hypertension is often included in the disorder spectrum of preeclampsia, particularly if 
other symptoms are present. Clinical findings in gestational hypertension are often intermediate 
between normal pregnancy and preeclampsia [1]. In general, placental, renal, or hepatic involvement 
are not present in gestational hypertension, and outcomes are better for mother and baby [1]. 
Metabolomics represents a “top-down” view of the metabolism, which more closely characterises 
the phenotype of the organism than genomic and proteomic applications. Metabolomics is the 
detection and semi-quantitation of low molecular weight metabolites present in cells, tissues or body 
fluids, using high throughput analysis platforms such as proton nuclear magnetic resonance (1H NMR) 
spectroscopy or Mass Spectrometry (MS) [10,11]. Recent interest has mounted in the metabolomics 
approach to predict and characterize preeclampsia. Early and late preeclampsia has been predicted 
using serum from weeks 11+0–13+6 of pregnancy in combination with maternal markers [12,13], and 
markers of preeclampsia have been found in urine and serum in the second trimester using 
metabolomics [14–17]. To date, no studies have attempted to predict hypertensive disorders in 
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pregnancy using 1H NMR analysis of urine and serum from early pregnancy in a complete prospective 
cohort of women. 
The aim of this study was to evaluate whether metabolic profiles of urine and serum collected from 
a cohort of women at gestational week 11+0–13+6 could predict preeclampsia and/or gestational 
hypertension. Secondly, we aimed to elucidate the metabolic changes that may accompany the early 
stages of these hypertensive disorders of pregnancy. 
2. Results 
2.1. Characteristics of the Study Participants 
A total of 640 women (585 nulliparous and 55 parous women) attended the study visit between 11+0 
and 13+6 weeks gestation. A flow chart describing the women included in the analysis is shown in 
Supplementary Figure S1. After exclusions for conditions appearing at or after the study visit as 
described in [9], and technical reasons (failed acquisitions or missing samples), 599 women remained 
in total with 587 urine samples and 591 serum samples. One excluded urine sample was from a woman 
who developed gestational hypertension. 
Characteristics of the study participants for each pregnancy outcome group are shown in Table 1. 
Twenty-six women (4.3%) later developed preeclampsia and 21 women (3.5%) later developed 
gestational hypertension. Of the nulliparous women, 3.8% developed preeclampsia and 2.9% 
gestational hypertension. Of the multiparous women, 12.2% developed preeclampsia and 9.8% 
gestational hypertension. One woman experienced early onset preeclampsia (delivery <34 weeks 
gestation) and one woman with gestational hypertension delivered before 34 weeks gestation. Two of 
the preeclamptic women had neonates classified as small for gestational age. Body mass index (BMI) 
at study enrolment was higher in women later developing gestational hypertension, and gestational age 
at birth and birth weights were lower for the neonates born in preeclamptic pregnancies. MAP was higher 
in women who later developed preeclampsia or gestational hypertension, but below the definition of 
chronic hypertension. 
Table 1. Characteristics of the study participants at time of enrolment related to pregnancy outcome. 
Characteristics  
(Stratified Per Pregnancy Outcome) Preeclampsia
Gestational 
Hypertension 
Normotensive 
Pregnancies p-value 
a 
Number of women included 26 21 552 - 
Age in years, median (IQR) 26 (7) 28 (6) 28 (5) NS 
BMI at enrolment in kg/m2, median (IQR) 24.8 (5.6) 27.1 (7.6) 23.5 (4.9) <0.01 
Smoking, n (%) b 4 (15.3) 2 (9.5) 63 (11.4) NS 
MAP at enrolment, median (IQR) 87.0 (11.1) 92.1 (8.1) 82.7 (8.8) <0.001 
UtAPI at enrolment, median (IQR) 1.75 (0.70) 1.49 (0.39) 1.46 (0.52) <0.05 
GA at enrolment, weeks, median (IQR) 13.1 (0.6) 13.1 (0.7) 12.9 (0.9) NS 
GA at delivery, weeks, median (IQR) 38.0 (3.1) 40.1 (1.3) 40.2 (1.9) <0.001 
Birth weight, g, median (IQR) 3243 (705) 3460 (1096) 3475 (600) <0.01 
Abbreviations: BMI, body mass index; GA, gestational age; IQR, interquartile range; MAP, mean arterial 
pressure; NS, not significant; UtAPI, uterine artery pulsatility index. a p-values calculated by nonparametric 
Kruskal-Wallis test for continuous variables or Fishers exact test for categorical variables; b The women were 
asked at the study visit whether they had smoked at any time during the pregnancy. 
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Identification of 54 urine metabolites and 30 serum metabolites was achieved (Supplementary 
Tables S1 and S2). The exploratory principal component analysis (PCA) (Figure 1) of the urine and 
serum 1H NMR spectra showed a characteristic clustering of urine samples from women who later 
developed preeclampsia or gestational hypertension, indicating a difference in urinary metabolic profiles 
between healthy and later hypertensive pregnancies. No apparent clustering was seen in serum samples. 
 
Figure 1. Score plots from principal component analysis (PCA) of urine and serum 
spectra. PCA score plots of the first and second principal components (PCs) with the 
percent variance explained, performed on urine samples (a,b) and serum samples (c,d). 
Urine samples gave a clustering of women set to develop preeclampsia (PE)  
(red diamonds, n = 26) or gestational hypertension (GH) (green triangles, n = 21), while 
serum samples gave no apparent clustering. Samples from women without hypertensive 
disorders of pregnancy are shown in blue circles n = 552. 
2.2. Metabolic Biomarkers in Urine 
Preeclampsia, gestational hypertension and both combined were predicted with urine metabolic 
profiles using partial least squares discriminant analysis (PLS-DA). The prediction parameters are 
given in Table 2, and additional model characteristics (latent variables, permutation results) are given 
in Supplementary Table S3). At 10% false positive rates (FPR) using metabolomics analyses with 
variable selection, preeclampsia could be predicted at 51% sensitivity from first trimester urine 
samples, gestational hypertension with 40% sensitivity, and both combined at 37% sensitivity. The 
loading plots from PLS-DA pinpoint the metabolites that are different between the modelled groups 
(Figure 2, Table 2). Scores and loading plots for the PLS-DA models are shown in Supplementary 
Figures S2–S4. Women that later developed preeclampsia had increased urine levels of creatinine, 
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glycine, 4-deoxythreonic acid, α-hydroxyisobutyrate, histidine and dimethylamine and decreased 
hippurate, lactate and proline betaine. For women developing gestational hypertension there was an 
additional decrease of urinary citrate excretion. 
Table 2. Urine metabolite multivariate models predicting preeclampsia and/or gestational hypertension a. 
Hypertensive 
Pregnancy 
Outcome 
Accuracy 
(%) 
Specificity 
(%) 
Sensitivity 
(%) 
Sensitivity at 
10% FPR (%) 
p-Value b Indicated Metabolites c 
Preeclampsia (n = 26) vs. no preeclampsia (n = 561) 
Full urine 
spectra 
61.4 65.3 57.5 11.3 <0.01 
↑ Crn, Gly, α-HIB, Hist, DMA 
↓ Hipp, Lac/Thr, ProlB 
VIP ≥ 1 
variables 
68.2 60.1 76.3 23.8 <0.01 
↑ Crn, Gly, α-HIB, Hist, DMA 
↓ Hipp, Lac/Thr 
CARS 
variables 
70.8 74.2 67.5 51.3 <0.01 
↑ Gly, 4-DEA, DMA  
↓ Hipp, Lac, Cre, ProlB  
Gestational hypertension (n = 20) d vs. no gestational hypertension (n = 567) 
Full urine 
spectra 
59.1 68.2 50.0 11.7 <0.01 
↑ Crn, α-HIB, DMA  
↓ Hipp, Lac/Thr, ProlB, Citrate 
VIP ≥ 1 
variables 
63.7 65.7  61.7 16.7 0.01 
↑ Crn, α-HIB, DMA  
↓ Hipp, Lac/Thr, ProlB, Citrate 
CARS 
variables 
63.8 89.3 38.3 40.0  0.04 
↑ DMA  
↓ PAG, Ala 
Preeclampsia or gestational hypertension (n = 46) vs. normotensive (n = 541) 
Full urine 
spectra 
61.5 56.1 66.8 14.4 <0.01 
↑ Crn, α-HIB, DMA,  
↓ Hipp, Lac/Thr, ProlB  
↑ Crn, α-HIB, DMA  
↓ Hipp, Lac/Thr, ProlB 
VIP ≥ 1 
variables 
64.0 56.2 71.9 20.0 <0.01 
CARS 
variables 
66.4 75.9 56.9 36.9 <0.01 
↑ α-HIB, DMA  
↓ Hipp, PAG, Lys, Ala 
Abbreviations: 4-DEA, 4-deoxythreonic acid; α-HIB, α-hydroxyisobutyrate; Ala, alanine; Cre, creatine; Crn, 
creatinine; CARS, competitive adapted reweighted sampling; DMA, dimethylamine; FPR, false positive rate; 
Gly, glycine; Hipp, hippurate; Hist, histidine; Lac, lactate; Leu, leucine; PAG, phenylacetylglutamine; ProlB, 
proline betaine; Thr, threonine; VIP, variable importance in projection. a VIP or CARS variable selection was 
performed, and results were evaluated using accuracy, specificity and sensitivity from double cross 
validation; b Model validity was estimated by 100 permutation tests; c The metabolites are listed as increased 
(↑) or decreased (↓) in the hypertensive disease pregnancies compared to the pregnancies without the disease;  
d One urine sample was missing from the gestational hypertension cases. 
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Figure 2. Urine 1H NMR variables involved in predicting preeclampsia (PE), gestational 
hypertension (GH) and both combined using partial least squares discriminant analysis 
(PLS-DA). The variable importance in projection (VIP) scores for each variable (part per 
million, ppm) are shown on the vertical axis, with higher VIP scores meaning increasing 
importance in the predictive model. The variables are colored by the loadings from the 
corresponding PLS-DA model. Red means increasing levels of metabolite in the  
indicated condition and blue meaning decreasing levels. Metabolites by number:  
1, 4-deoxyerythronic acid; 2, 4-deoxythreonic acid; 3, lactate and threonine;  
4, α-hydroxyisobutyrate; 5, alanine; 6, acetate and lysine; 7, glutamine; 8, citrate;  
9, dimethylamine; 10, creatinine; 11, proline betaine; 12, carnitine (tentative); 13, betaine; 
14, glycine 15, ascorbic acid; 16, hippurate; 17, phenylacetylglutamine; 18, histidine. 
2.3. Metabolic Biomarkers in Serum 
Preeclampsia, gestational hypertension and both combined were predicted with serum metabolic 
profiles using PLS-DA. The prediction results are given in Table 3, and additional model parameters 
and permutation results are given in Supplementary Table S4). At 10% FPR, 15%, 33% and 30%, 
respectively, of preeclampsia, gestational hypertension and both combined could be predicted. The 
loading plots from PLS-DA pinpoint the metabolites that are different between the hypertensive groups 
(Figure 3, Table 3). Scores and loading plots for the significant PLS-DA models are shown in 
Supplementary Figures S5 and S6. Mainly, increased lipid levels were evident in both hypertensive 
groups, and primarily the increased signals originated from triglycerides. Decreased levels of 
phosphatidylcholines, with signals originating from lipids in high density lipoproteins (HDL), glucose, 
lactate and alanine, were also important for the prediction of hypertensive disorders. 
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Table 3. Serum metabolite multivariate models predicting preeclampsia and/or  
gestational hypertension a. 
Hypertensive 
Pregnancy 
Outcome 
Accuracy 
(%) 
Specificity 
(%) 
Sensitivity 
(%) 
Sensitivity at 
10% FPR (%) 
p-Value b Indicated Metabolites c 
Preeclampsia (n = 26), vs. no preeclampsia (n = 565) 
Full serum spectra 59.4 73.8 45.0 20.0 >0.05 NS 
VIP ≥ 1 variables 58.3 70.3 46.3 26.3 >0.05 NS 
CARS variables 64.6 65.4 63.8 15.0 0.05 
↑ Signals from 
triglycerides, 3-HB,  
↓ Pyruvate, PtdCho, Lac 
Gestational Hypertension (n = 21) vs. no gestational hypertension (n = 570) 
Full serum spectra 59.1 74.8 43.3 25.0 >0.05 NS 
VIP ≥ 1 variables 58.1 75.0 41.3 22.5  >0.05 NS 
CARS variables 66.1 55.0 76.9 33.3 0.02 
↑ Signals from 
triglycerides,  
↓ Variables corresponding 
to HDL, Lac, N-Ac, 
PtdCho, Glc 
Preeclampsia or gestational hypertension (n = 47) vs. normotensive (n = 544) 
Full serum spectra 62.6 70.8 54.4 24.4 0.01 
↑ Lipid signals, signals 
from triglycerides,  
↓ Signals from HDL, Glc, 
Val, Leu, Lac,  
Ala, PtdCho 
VIP ≥ 1 variables 63.0 70.4 55.6 27.5 <0.00 
↑ Lipid signals, signals 
from triglycerides,  
↓ Signals from HDL, Glc, 
Leu, Val, Ala,  
Lac, PtdCho 
CARS variables 64.5 69.1 60.0  30.0 0.02 
↑ Variables corresponding 
to triglycerides,  
↓ Lac, PtdCho 
Abbreviations: 3-HB, 3-hydroxybutyrate; Ala, alanine; CARS, competitive adaptive reweighted sampling; 
FPR, false positive rate; GH, gestational hypertension; Glc, glucose; HDL, high density lipoprotein;  
Lac, lactate; Leu, leucine; N-Ac, N-acetyl glycoproteins; NS, not significant PE, preeclampsia;  
PtdCho, phosphatidylcholine; Thr, threonine; Val, valine; VIP, variable importance in projection. a VIP or 
CARS variable selection was performed, and results were evaluated using accuracy, specificity and 
sensitivity from double cross validation; b Model validity was estimated by 100 permutation tests; c The 
metabolites are listed as increased (↑) or decreased (↓) in the hypertensive disease pregnancies compared to 
the pregnancies without the disease. 
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Figure 3. Serum variables involved in predicting preeclampsia and/or gestational 
hypertension by partial least squares discriminant analysis PLS-DA. The variable 
importance in projection (VIP) scores for each variable are shown along the vertical axis. 
The variables are colored by the loadings as described in Figure 3. Abbreviations: HDL, 
high density lipoprotein; Leu, leucine; N-Ac, N-acetylated carbohydrate side chains of 
glycoproteins; PtdCho, phosphatidylcholine; Py, pyruvate; Val, valine. 
2.4. Combined Metabolic and Clinical Biomarkers Predict Preeclampsia 
Metabolites were combined with maternal characteristics to predict preeclampsia. The best logistic 
regression models for prediction of preeclampsia are shown in Table 4. Urinary hippurate:creatinine 
combined with maternal MAP and a variable denoting age >35 or <20 at enrolment gave better 
prediction rates (AUC 0.778) compared to UtAPI combined with MAP and age (AUC 0.738)  
(Figure 4). Urine metabolites glycine, proline betaine, lactate, dimethylamine, and 4-deoxythreonic 
acid to creatinine ratios did not contribute significantly to the logistic regression models. 
Table 4. Prediction of preeclampsia based on urinary metabolites and maternal 
characteristics in logistic regression. 
Variable AUC (95% CI) Sensitivity (%) a PPV NPV p-Value b 
Hippurate/creatinine ratio c 0.694 (0.595–0.793) 0.192 0.082 0.960 0.004 
MAP, age d, UtAPI 0.738 (0.637–0.839) 0.346 0.138 0.967 <0.001 
Metabolites, MAP, age d 0.778 (0.695–0.862) 0.423 0.164 0.971 <0.001 
Metabolites, MAP, age d, UtAPI 0.807 (0.721–0.893) 0.538 0.200 0.977 <0.001 
Abbreviations: AUC, area under the receiver operator characteristic curve; CI, confidence interval; MAP, 
mean arterial pressure at enrolment; NPV, negative predictive value; PPV, positive predictive value; UtAPI; 
uterine artery pulsatility index at enrolment. a Sensitivity is given at 10% false discovery rate; b Omnibus  
chi-square significance level of the model; c Metabolites were chosen based on selection in the multivariate 
models and the metabolite/creatinine ratios used in logistic regression. The final metabolites selected were 
hippurate/creatinine ratio in urine; d Women with maternal age <20 or >35 were categorised as high risk. 
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Figure 4. Receiver Operator Characteristic (ROC) curve comparison from logistic 
regression analyses. Prediction of preeclampsia using logistic regression, with risk of 
preeclampsia as dependent variable and maternal age and MAP in combination with 
urinary metabolites (Hippurate and Creatinine) or UtAPI as independent variables. 
Abbreviations: MAP, Mean Arterial Pressure; UtAPI, Uterine Artery pulsatility index. 
3. Discussion 
Metabolic profiles in urine and serum samples from pregnant women at 11+0–13+6 weeks gestation 
were significantly different between women who developed preeclampsia or gestational hypertension, 
and women with normotensive pregnancies. Both urine and serum metabolic profiles could  
predict preeclampsia and gestational hypertension, with urine profiles giving the best prediction.  
Decreased urinary hippurate, increased urinary creatinine, and increased levels of serum lipids were  
the most important metabolic differences identified in women who later developed preeclampsia or  
gestational hypertension. 
This is the first metabolomics study performed on first trimester urine samples for prediction of 
preeclampsia and gestational hypertension. Changes in hippurate excretion preceding preeclampsia are 
novel to this study. Decreased urinary hippurate has been shown to correlate with increased blood 
pressure [18], and may be related to diet or to blood pressure related changes in the gut microflora, 
where this metabolite is produced [18,19]. Hippurate and proline betaine excretion to the urine may 
increase with fruit intake [20], and the reduced excretion of these metabolites in urine of women who 
later developed preeclampsia may indicate a healthier diet for the normotensive group. The predictive 
metabolic profile for preeclampsia also included increased glycine and 4-deoxythreonic acid, as well as 
decreased lactate and creatine. 4-Deoxythreonic acid is a degradation product of 3-hydroxybutyrate [21], 
which is shown increased in maternal serum in our study. Both preeclampsia and gestational 
hypertension was associated with an increase in urinary dimethylamine. This metabolite may have 
dietary origins [22], but is also derived from asymmetric dimethylarginine, a biomarker of increased 
cardiovascular risk [22,23]. Preeclampsia has been successfully predicted previously with second 
trimester urine in a NMR metabolomics case-control study [14]. Those results also include increased  
4-deoxythreonic acid [14]. However, many of the metabolites were not the same as those highlighted 
here, including the hippurate to creatinine ratio, which might be attributed to the difference in 
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gestational age between the studies resulting in changing metabolic profiles [24]. Non-metabolomics 
methods have been used to predict preeclampsia from urine samples, focusing on urinary albumin to 
creatinine ratios as a measure of kidney function [25], and creatinine levels in urine [26]. Increased 
urinary creatinine was found to be predictive of preeclampsia in a study as early as 8–10 weeks 
gestation [26]. Our corresponding findings of increased creatinine in urine may be an effect of the 
increased BMI and MAP of the women who developed preeclampsia and gestational hypertension [26],  
or possibly a marker of early renal involvement. Studies have reported increased glomerular filtration 
rates in pre-hypertensive subjects [27]. Urinary citrate was decreased in women who later developed 
gestational hypertension. These women had higher BMI, and an inverse relation between citrate 
excretion and adiposity has recently been found [28]. The metabolic changes preceding preeclampsia 
and gestational hypertension were otherwise comparable, suggesting that the risk profiles visible to 
NMR metabolomics are similar for hypertensive disorders of pregnancy, while other measurements 
such as the UtAPI may to a larger extent reflect a difference between the two diseases. 
First-trimester maternal plasma or serum is more commonly used for prediction of preeclampsia by 
metabolomics methods [12,13,16,29]. In a previous case-control study, a model with maternal 
characteristics combined with four NMR-measured serum metabolites predicted late onset PE and 
pointed to disturbed lipid metabolism [12]. MS-based metabolomics studies have found increased 
serum levels of carnitine, fatty acid and lipid classes to predict preeclampsia [16,29]. However, no 
previous studies have used metabolomics to predict the related disease gestational hypertension at  
an early stage of pregnancy. Changes in lipid metabolism evident early in pregnancies of women  
who develop hypertensive disorders of pregnancy have been established [30–32]. Abnormal lipid 
metabolism may play a role in the aetiology of preeclampsia [32]. Elevated lipid and low-density 
lipoprotein levels in maternal serum may induce endothelial dysfunction secondary to oxidative  
stress [30]. Decrease in phosphatidylcholine serum levels related to both gestational hypertension and 
preeclampsia may indicate altered choline metabolism [33]. Choline is an essential nutrient which 
functions in phospholipid metabolism, and choline levels may influence inflammation and 
angiogenesis [33–35]. Decreases in phosphatidylcholines have also been found in individuals with 
increased cardiovascular risk factors [36]. The decrease in serum pyruvate concurrent with the increase 
in 3-hydroxybutyrate in women who later developed preeclampsia may indicate an early shift in 
metabolism from glycolysis to ketosis for energy production [37], and this was also reflected in the 
urine metabolic profiles. 
Combining urinary hippurate to creatinine ratios with maternal MAP and age increased the 
prediction rates of preeclampsia compared to using the uterine artery Doppler measurement with MAP 
and age. Replacing the UtAPI measurement, which requires skilled ultrasound technicians and time, 
with an easily accessible urinary marker, would be an advantage especially in low resource areas. 
However, clinical application of the metabolic profiling prediction method will require confirmation in 
cohorts from other populations, where the metabolites identified in this study form the basis of 
prediction. Currently, early identification of women at risk for developing hypertensive pregnancy 
disorders would enable a closer follow-up of these women [38]. Extensive research is currently 
examining potential prophylactic treatment, especially for preterm or severe preeclampsia [4,39,40].  
In order for these treatments to work, it is important to identify the women at risk for developing the 
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disease at an early time point. This study shows that there is potentially predictive information contained 
in a simple urine sample. 
The prediction of preeclampsia and gestational hypertension using metabolic profiling of urine 
performed with similar sensitivity as previous approaches using maternal biophysical and biochemical 
markers on the same cohort [9,41], and in other studies [5,8], while the serum metabolic profiling did 
not predict the syndromes very well. This may reflect the lower sensitivity of 1H NMR spectroscopy to 
detect small molecular weight metabolites in serum, due to viscosity, lipid signal overlap and lower 
concentrations of 1H NMR-visible metabolites. However, the large contribution to the model from the 
lipid regions of the spectra indicate that a lipidomic approach could give additional information about 
the first-trimester maternal serum changes related to preeclampsia. 
The major strength of our study was the prospective design with complete follow-up of almost  
600 women with medium to high risk of preeclampsia. The multivariate statistical analyses were 
performed up to standards of the field, with rigid cross validation [42]. Weaknesses of our study 
include the limited numbers of cases, which is difficult to overcome given the low incidence of the 
disorders. An advantage with multivariate analyses as used in metabolomics approaches is that the 
covariance between metabolites is taken into account in the modelling. However, in order to more 
conveniently translate metabolic findings to the clinic, a selection of metabolites could be made which 
convey most of the information contained in the source. Combining sets of metabolites with maternal 
characteristics may improve the prediction rates. Previous publications within the metabolomics field 
have used case-control studies, or samples obtained at a later gestational age, to demonstrate a 
difference in metabolic profile before onset of preeclampsia [12,13,16,29,43]. This study aimed to 
predict two hypertensive disorders of pregnancy in a prospective cohort of women, and this study 
design more accurately reflects the predictive power of a metabolomics approach than a case-control 
design. This difference in design may also explain why our results have lower prediction rates 
compared to previous metabolic case-control studies. 
The sensitivity of prediction of preeclampsia using metabolic biomarkers in this study (51% at  
10% FPR) was markedly higher than previously published prediction of preeclampsia based on clinical 
markers such as MAP, maternal age and UtAPI in the same cohort (38.5%) [9] and in another 
nulliparous cohort (37%) [44]. However, the achieved sensitivity of prediction of preeclampsia shown 
here is not high enough for clinical implementation, and the presented model warrants validation in 
other cohorts. 
4. Experimental Section 
4.1. Study Population 
The study population has previously been described in detail [9,42]. Briefly, pregnant women who 
were nulliparous or had preeclampsia or gestational hypertension in a previous pregnancy were invited 
to attend an examination at 11+0–13+6 weeks of gestation (crown-rump length 45–84 mm). At the study 
visit participants were interviewed about their health and pregnancy. All participants were weighed, and 
BMI was calculated in kg/m2. The women were asked to fast for one hour before their visit to avoid 
immediate effects of meals on the metabolic profiles. Venous blood was drawn into non-heparinised 
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tubes, left to clot for 30 min at room temperature, and centrifuged at 1800× g for 10 min. A serum 
sample (0.8 mL) was separated and stored at −80 °C, thawed once and an aliquot of 120 μL was stored 
at −80 °C. Spot urine samples were collected at the study visit and aliquots (1.8 mL) were stored 
directly at −80 °C. Blood pressure was measured with a CAS 740 MAX NIBP automated device (CAS 
Medical systems Inc., Branford, CT, USA) [45]. MAP from the arm with the highest MAP was used. 
Participants were examined with transabdominal ultrasound with a Siemens ACUSON Antares™ 
machine (Siemens Medical Solutions Inc., Santa Clara, CA, USA), and the UtAPI was measured [46]. 
The UtAPI was measured three times on each side, and the average of three measurements on each side 
was used. The average of the two sides was used in calculations. All scans were carried out by specialized 
trained midwifes who were certified by the Fetal Medicine Foundation (http://www.fetalmedicine.com). 
Data on pregnancy outcomes were collected from hospital records. Preeclampsia was defined as 
systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg in combination with 
proteinuria ≥0.3 g per 24 h measured twice within 4–6 h by dipstick ≥+1, occurring after gestational 
week 20 [47]. Gestational hypertension was defined as the previously described hypertension 
occurring without proteinuria after gestational week 20. Early onset preeclampsia was defined as 
preeclampsia with delivery before 34 weeks of pregnancy, and late onset preeclampsia with delivery 
after 34 weeks. For estimation of weight deviation at birth, the normal values from Marsal et al. were 
applied [48]. The definition of small for gestational age was birthweight with a mean below two 
standard deviations (22%). All women gave written informed consent at study entry. The study was 
approved by the Regional Committee for Medical Research Ethics in mid-Norway, entries REK 
2010/102 and 2013/386. 
4.2. 1H NMR Metabolomic Analyses 
Laboratory analyses were done after all women had delivered their babies. Urine samples were 
thawed on ice and centrifuged at 5600× g (Sorvall RMC 14; DuPont, Wilmington, NC, USA) for  
five minutes. The supernatant (540 μL) was mixed with a bacteriostatic buffer (60 μL) (pH 7.4,  
1.5 mM KH2PO4 in D2O, 0.1% Trimethyl-Silyl Propionate (TSP), 2 mM NaN3) (Receipt from Bruker 
Biospin AG, Reinstetten, Germany) and transferred to 5 mm NMR tubes (Bruker Biospin, Billerica, 
MA, USA). Serum samples were thawed on ice. Serum (100 μL) was mixed with a bacteriostatic buffer  
(100 μL) (pH 7.4 0.075 mM Na2HPO4, 5 μM NaN3, 5 μM TSP) (Bruker Biospin) and transferred to  
3 mm NMR tubes. 
NMR analysis was performed at the MR Core Facility at the Norwegian University of Science and 
Technology (NTNU), Trondheim, Norway using a Bruker Avance III Ultrashielded Plus 600 MHz 
spectrometer (Bruker Biospin GmbH, Rheinstetten, Germany) equipped with a 5 mm QCI Cryoprobe 
with integrated, cooled preamplifiers for 1H, 2H and 13C. Experiments were fully automated using the 
SampleJet™ in combination with Icon-NMR on TopSpin 3.1 software (Bruker Biospin). The 1H NMR 
analyses were performed blinded to pregnancy outcomes. 1H NMR spectroscopy acquisition 
parameters are described in Supplementary Table S1. One-dimensional Standard Nuclear Overhauser 
Effect spectroscopy (NOESY) (noesygppr1d; Bruker Biospin) spectra were acquired on the urine 
samples for quantitative detection of small molecular weight metabolites. On the serum samples,  
Carr-Purcell-Meiboom-Gill (CPMG) (cpmgpr1d; Bruker Biospin) spectra were acquired. In CPMG 
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spectra, signals from macromolecules have been filtered out for better detection of small molecular 
weight metabolites. For additional aid in metabolite identification, two-dimensional spectra were 
acquired (Supplementary Table S5). 
Spectra were automatically Fourier transformed, phased and baseline corrected in TopSpin with a 
line broadening of 0.3Hz. Spectra were imported to Matlab r2013b (The Mathworks Inc., Natick, MA, 
USA). Urine spectral regions containing metabolites of interest (δ 0.5 to 9.0 ppm) were extracted and  
the residual H2O and urea signals removed. Peaks in the urine spectra were aligned by the iCoshift  
algorithm [49] with 245 manually chosen intervals, using the spectrum with the highest correlation as the 
reference [50]. The urine spectra were normalised using probabilistic quotient normalization to account 
for differences in dilution [51]. Finally the data was pareto scaled and mean centered [52]. Serum 
spectral regions containing metabolites of interest (δ 0.1 to 4.2 ppm) were extracted and aligned by the 
left alanine doublet peak at 1.48 ppm. The spectra were normalised to unit area and mean centered. 
Raw spectral data are available on request. 
4.3. Statistical Analysis 
Statistical analyses were done in Matlab and in Statistical Package for the Social Sciences (SPSS) 
(version 20.0; SPSS Inc., Chicago, IL, USA). Baseline characteristics of the study population were 
tested for normality using the Kolmogorov-Smirnov test [53]. Non-normal data was reported as 
median (25th–75th percentile), normal data as mean (standard deviation), and categorical data as 
number (percentage) using either the Kruskal-Wallis test, analysis of variance (ANOVA), or Fishers 
exact test. The metabolic data was explored for clusters and outliers using PCA as described below.  
The predictive potential of the metabolic profiles for preeclampsia, gestational hypertension, and both 
combined were evaluated using PLS-DA. The predictive values of urine and serum 1H NMR spectra 
were evaluated by sensitivity at 10% false positive rate and at the best cutoff on the Receiver Operator 
Characteristic (ROC) curve. 
PCA is a powerful method of data extraction which finds combinations of variables, called principal 
components (PCs), describing the main variation in large data. These are visualised in scores and 
loading plots, making it possible to visualise high dimensional data using only a few dimensions.  
The score plots show each spectrum as an object in the PC space, and are useful for identifying 
clusters, trends and outliers in the dataset. The loading plots show the variable’s contributions for 
defining each PC. PLS-DA models the relationship between the spectra and class information using 
multivariate regression methods, and is used to establish prediction models. The metabolites 
responsible for separation between classes are given by the latent variables (LVs) [54]. Similar to 
PCA, the resulting model can be visualised in scores and loading plots. Variable Importance in 
Projection (VIP) is a method of assessing which variables are most important to the prediction. 
Variables with VIP scores ≤1 can be considered irrelevant to the prediction and excluded [55]. 
Competitive Adaptive Reweighted Sampling (CARS) is a variable selection method that iteratively 
selects variable subsets that perform best in cross validated regression [56]. 
Multivariate models were constructed using PLS Toolbox 7.3.1 (Eigenvector Research, Wenatchee, 
WA, USA). Preeclampsia, gestational hypertension and both disorders combined were predicted 
within the entire cohort; e.g., for prediction of preeclampsia the gestational hypertension remained in 
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the control group. The input to the classification models was either full, preprocessed spectra, or sets of 
variables selected by different variable selection algorithms (VIP or CARS). VIP selection was 
performed by creating a five-fold cross validated model, then selecting variables with VIP >1 to use in a 
further model [55]. CARS variable selection was performed with five-fold cross validation and 50 Monte 
Carlo samplings [57]. The classification models were evaluated using a double cross validation 
procedure [57]. A set of samples (20%) is set aside for independent validation of the model (the outer 
loop). The remaining samples are split into an inner calibration and test set used for determining the 
optimal number of PLS components as defined by the lowest prediction error. The inner and outer 
loops are both repeated 20 times. The data was split so that the ratio of case to control samples was the 
same in validation, calibration and test sets. Mean sensitivity, specificity and classification accuracy 
were calculated from the outer validation set. The PLS-DA classification results were validated using 
permutation testing on the classification error rates, with p-values ≤0.05 considered significant. 
Permutation testing performs classification on reshuffled classes, and tests whether those prediction 
results are significantly different from prediction of randomised classes [57]. One hundred permutations 
were built for each predictive model. 
Finally, urine metabolites found to be important to the multivariate predictions based on high VIP 
scores and/or CARS selection (hippurate, lactate, dimethylamine, and 4-deoxythreonic acid to 
creatinine ratios) were quantified by measuring the area under the curve in the 1H NMR spectra.  
The metabolites were input to logistic regression models alone and in combination with maternal 
characteristics. The maternal variables found to give the best prediction of preeclampsia in the same 
cohort by Skråstad et al. [9] (UtAPI, MAP and maternal age) were combined with selected metabolite 
ratios, in order to improve the prediction rates for preeclampsia in the cohort. Preeclampsia was 
predicted using maternal MAP and age as variables in combination with metabolite ratios. Women 
with maternal age above 35 or less than 20 years were categorised as high risk [58]. The results were 
compared to prediction rates obtained using UtAPI, MAP and age. Logistic regression analyses were 
done in SPSS (version 20.0; SPSS Inc., Chicago, IL, USA). 
5. Conclusions 
Metabolic profiling of urine and serum in early pregnancy revealed specific, significant changes in 
the metabolism of women who later developed preeclampsia or gestational hypertension. Preeclampsia 
and gestational hypertension could be successfully predicted in early pregnancy using urine and serum 
metabolic profiles. The consistent changes in the urinary metabolome represent an attractive avenue 
for clinical prediction, since spot urine is easily accessible. Combining a panel of urine metabolites 
with maternal characteristics may improve the accuracy of prediction of preeclampsia. 
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